Diagnostics Accelerator: Digital Biomarkers in Alzheimer's Disease


The Diagnostics Accelerator is a partnership of funders dedicated to accelerating the development of affordable and accessible biomarkers for Alzheimer's disease, frontotemporal degeneration, and other related dementias. The Diagnostics Accelerator supports research and development through translational research awards and access to consulting support from industry experts. The current RFP is soliciting projects to develop and validate digital biomarkers for Alzheimer's disease and related dementias. Digital biomarkers are defined as objective, quantifiable physiological and behavioral data that are collected, measured and analyzed by means of digital devices such as portables, wearables, or ambient sensors. Digital biomarkers range from computerized or app-based versions of traditional neurocognitive tests to novel technology platforms that combine multiple complex data sources into a phenotypic signature.

Proposals addressing a range of potential clinical uses are of interest, especially technologies for early assessment and those aiding in diagnosis and monitoring treatment response or rate of disease progression. Creative approaches to leverage new and existing software and hardware are encouraged. Importantly, the use of the digital technology should be driven by 1) an unmet patient or scientific need for a better assessment and/or 2) providing a more cost-effective, efficient, and less burdensome approach to diagnosis and monitoring in clinical practice and clinical trials.


Funding is open to researchers and clinicians worldwide at:

  • Academic medical centers and universities or nonprofits
    Industry partnerships are strongly encouraged.
  • Biotechnology companies
    Funding is provided through mission-related investments that require return on investment. Existing companies and new spinouts are both eligible.

For program-related inquiries, please contact:
Nicole Bjorklund, PhD, Assistant Director, Scientific Affairs

For application submission inquiries, please contact:
Grants and Mission-Related Investments Team


Must be received by 5:00 pm ET on the deadline date.

Letter of Intent:
June 7, 2019

This is the final deadline for applicants to submit letters of intent. Letters of intent will be accepted and reviewed on a rolling basis up until this deadline.

Invited Full Proposal:
August 16, 2019

Agency Name: 
Alzheimer's Drug Discovery Foundation -
Contact Name: 
Penny D'Agnone
Grant Location: 
External Deadline: 
Friday, June 7, 2019
Grant Type: 
Grant Area: 
Grant Eligibility: